Abstract:Viral vectors have been used for a broad spectrum of gene therapy for both acute and chronic diseases. In the context of cancer gene therapy, viral vectors expressing anti-tumor, toxic, suicide and immunostimulatory genes, such as cytokines and chemokines, have been applied. Oncolytic viruses, which specifically replicate in and kill tumor cells, have provided tumor eradication, and even cure of cancers in animal models. In a broader meaning, vaccine development against infectious diseases and various cancers has been considered as a type of gene therapy. Especially in the case of COVID-19 vaccines, adenovirus-based vaccines such as ChAdOx1 nCoV-19 and Ad26.COV2.S have demonstrated excellent safety and vaccine efficacy in clinical trials, leading to Emergency Use Authorization in many countries. Viral vectors have shown great promise in the treatment of chronic diseases such as severe combined immunodeficiency (SCID), muscular dystrophy, hemophilia, β-thalassemia, and sickle cell disease (SCD). Proof-of-concept has been established in preclinical studies in various animal models. Clinical gene therapy trials have confirmed good safety, tolerability, and therapeutic efficacy. Viral-based drugs have been approved for cancer, hematological, metabolic, neurological, and ophthalmological diseases as well as for vaccines. For example, the adenovirus-based drug Gendicine® for non-small-cell lung cancer, the reovirus-based drug Reolysin® for ovarian cancer, the oncolytic HSV T-VEC for melanoma, lentivirus-based treatment of ADA-SCID disease, and the rhabdovirus-based vaccine Ervebo against Ebola virus disease have been approved for human use.

Viral vector‐based gene therapies in the clinic

Clinical and Translational Landscape of Viral Gene Therapies

Viral vector platforms within the gene therapy landscape

Immune Responses to Viral Gene Therapy Vectors

A primer to gene therapy: Progress, prospects, and problems

Viral Vectors in Gene Therapy: Where Do We Stand in 2023?

How Far Are Non-Viral Vectors to Come of Age and Reach Clinical Translation in Gene Therapy?

Clinical translation of gene medicine

Viral Vector Systems for Gene Therapy: A Comprehensive Literature Review of Progress and Biosafety Challenges

Non-viral Vectors in Gene Therapy: Recent Development, Challenges, and Prospects

Advances in Non-Viral DNA Vectors for Gene Therapy

Viral vectors for therapy of neurologic diseases

Current status of gene therapy vector research

Innate Immune Response to Viral Vectors in Gene Therapy

Optimization of lentiviral vectors generation for biomedical and clinical research purposes: contemporary trends in technology development and applications

The clinical landscape for AAV gene therapies

From unique challenges to inspired solutions: how vector engineering makes in vivo gene therapy possible

Current Clinical Applications of In Vivo Gene Therapy with AAVs

Gene Therapy Leaves a Vicious Cycle

Adeno-associated virus vector as a platform for gene therapy delivery

Non-viral vectors for gene-based therapy